- New data from the API ADAD Study to be presented in AAIC Focused Topic Session
- New Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer’s disease
- First-time presentation of innovative biomarker-based translational clinical trial design to evaluate ACI-24.060 in sporadic Alzheimer’s disease and in people with Down syndrome
- Additional data from proof-of-concept clinical study of ACI-12589 PET tracer to detect alpha-synuclein in the brains of living patients
LAUSANNE, Switzerland, July 22, 2022 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced 10 upcoming presentations that will be delivered at the Alzheimer’s Association International Conference (AAIC) in San Diego, California (United States) and online, July 31 – August 4, 2022.
Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “With new data on therapeutic and diagnostic candidates addressing multiple targets, the upcoming AAIC presentations will showcase our aim to shift the therapeutic paradigm towards earlier treatment and prevention in order to address Alzheimer’s and other neurodegenerative disease. We look forward to learning more about the impact of the API ADAD study. And, we are delighted to announce during AAIC the fourth of seven clinical readouts due this year: new results from our PI-2620 Tau PET tracer Phase 2 trial in people with Alzheimer’s disease.”
There will be multiple presentations by AC Immune’s partners with Genentech covering the crenezumab and semorinemab partnerships. New Phase 2 clinical Alzheimer’s data on the Tau-PET tracer PI-2620, partnered with Life Molecular Imaging (LMI), will be announced during the conference and presented at a workshop organized by LMI.
Additional presentations feature: new patient scans from the proof-of-concept clinical study of ACI-12589; AC Immune’s wholly owned alpha-synuclein PET tracer; and, new preclinical data on ACI-24.060, the Company’s wholly owned anti-Abeta vaccine. Preclinical data on ACI-12589 and the design of an innovative, adaptive translational Phase 1b/2a trial of ACI-24 in patients with Alzheimer’s disease and individuals with Down syndrome also will be presented.
AC Immune pipeline at AAIC 2022
|
Abstract Title |
|
| Crenezumab Abeta antibody | |
| API ADAD Colombia Trial initial findings: a randomized, double-blind, placebo-controlled, parallel- group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab |
|
| Clinical Profiles of Persons Who Progress to Cognitive Impairment in the Alzheimer’s Prevention Initiative (API) ADAD Colombia Trial |
|
| Semorinemab Tau antibody | |
| Evaluation Of Longitudinal [18F]GTP1 Tau Burden Metrics In The Tauriel Phase II Study |
|
| Selecting appropriate meaningful change thresholds for trials of early (prodromal-to-mild) AD: A caregiver-rated, anchor-based analysis based on the Tauriel Study |
|
| PI-2620 Tau-PET Tracer | |
| In Vivo Head-To-Head Comparison Of [18f]GTP1 And [18f]PI2620 In Alzheimer’s Disease |
|
| One year longitudinal change of Tau accumulation on [18F]PI-2620 PET in Alzheimer spectrum |
|
| ACI-12589 alpha-syn imaging agent | |
| Discovery of [18F] ACI-12589, a novel and promising PET-tracer for alpha-synuclein |
|
| Initial clinical scans using [18F]ACI-12589, a novel α-synuclein PET-tracer |
|
| ACI-24 anti-Abeta vaccine | |
| Optimized ACI-24, an amyloid beta (Abeta) vaccine that safely drives immunity to oligomers and pyroglutamate Abeta, key pathological species of Alzheimer’s disease (AD) |
|
| Biomarker-based development for optimized ACI-24, a novel candidate vaccine for the treatment and prevention of Alzheimer’s disease |
|
